Colorectal cancer: New advances in immunotherapy

Cancer Biology and Therapy

Volumn 6, Issue 1, 2007, Pages 11-17

  Cubas, Rafael ^a   Li, Min ^a   Chen, Changyi ^a   Yao, Qizhi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Active immunotherapy; Antibodies; Colorectal cancer; Passive immunotherapy; Vaccines

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CANCER VACCINE; CANVAXIN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; DENDRITIC CELL VACCINE; EDRECOLOMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; IDIOTYPIC ANTIBODY; IRINOTECAN; MATUZUMAB; MELANOMA VACCINE; MUCIN 1; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; TETANUS TOXOID; TUMOR CELL VACCINE;

ACNE; ACTIVE IMMUNIZATION; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DENDRITIC CELL; DRUG ERUPTION; DRUG HYPERSENSITIVITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MONOTHERAPY; NATURAL KILLER CELL; PASSIVE IMMUNIZATION; REVIEW; T LYMPHOCYTE; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR IMMUNITY; UNITED STATES;

EID: 33847125343     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.1.3672     Document Type: Review

References (64)

1. Weitz J, Koch M, Debus J, Höhler T, Galle Peter, Büchler M. Colorectal cancer. Lancet 2005; 365:153-65.
2. Xu R, Zhou B, Fung PCW, Li X. Recent advances in the treatment of colon cancer. Histol Histopathol 2006; 21:867-72.
3. Correale P, Cusi MG, Micheli L, Nencini C, del Vecchio MT, Torino F, Aquino A, Bonmassar E, Francini G, Giogi G. Chemo-immunotherapy of colorectal carcinoma: Preclinical rationale and clinical experience. Springer Science 2006; 24:99-110.
4. Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide. GLOBOCAN 2000 version 1.0 IARC CancerBase No. 5. IARC Press, Lyon.
5. Wils J, O'Dwyer P, Labianca R. Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann Oncol 2001; 12:12-22.
6. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immonol Rev 1999; 170:85-100.
7. Nagorsen D, Eckhard T. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 2006; 12(10):3064-69.
8. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res 2003; 9:4296-303.
9. Evans TR, Kaye SB. Vaccine therapy for cancer - Fact or fiction? Q J M 1999; 92:299-307.
10. Veronese ML, O'Dwyer P. Monoclonal antibodies in the treatment of colorectal cancer. European Journal of Cancer 2004; 40:1292-301.
11. Herlyn D, Sears H, Iliopoulos D, Lubeck M, Douillard JY, Sindelar W, Tempero M, Mellstedt H, Maher M, Koprowski H. Anti-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma 1986; Suppl 1:51-58.
12. Klee GG. Human anti-mouse antibodies. Arch Pathol Lab Med 2000; 124(6):921-23.
13. Liljefors M, Ragnhammar P, Nilsson B, Ullenhag G, Mellstedt H, Frodin JE. Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. Int J Oncol 2004; 3:703-11.
14. Armstrong A, Eck SL. EpCAM: A new therapeutic target for an old cancer antigen. Cancer Biology and Therapy 2003; 2:320-26.
15. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmair H, Hirche H, Pichlmayr R. Monoclonal antibody therapy for resected Duke'C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998; 16:1788-94.
16. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma: German Cancer Aid 17-1A Study Group. Lancet 1994; 343:1177-83.
17. Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: A randomised study. Lancet 2002; 360:671-7.
18. Chung KY, Saltz LB. Antibody-based therapies for colorectal cancer. Oncologist 2005; 10:701-9.
19. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004; 25:581-611.
20. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36:127-37.
21. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-5.
22. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: Clinical experience with bevacizumab. Oncologist 2004; 9(Suppl 1):11-18.
23. Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Griffing S, Novotny W, Holmgren E, Kabbinavar F. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC); results a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003; 22:906.
24. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37:S9-S15.
25. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71:2454-60.
26. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151:1523-30.
27. Saltz L, Meropol NJ, Loehrer PJ, Waksal H, Needle MN, Mayer RJ. Single agent IMC-C225 (ErbituxTM) has activity in CPT-11-refractory colorectal cancer (CRC) that express the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002; 21:A504.
28. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Van Cutsem E. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22:A1012.
29. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
30. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-10.
31. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol/Hematol 2001; 38:17-23.
32. Hecht J, Patnaik A, Malik I, Venook A, Berlin J, Croghan G, Wiens BL, Visonneau S, Jerian S, Meropol NJ. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. Presented at the 2004 American Society of Clinical Oncology Annual Meeting, New Orleans Louisiana 2004.
33. Meropol NJ, Berlin J, Hecht JR, Croghan A, Patnaik LM, Weiner MF, Sweed BL, Wiens D, Caron S. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22:A1026. 34. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6:29-31.
34. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A, Baselga J. Phase I study of the humanized anti-epidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22:175-84.
35. Lo KM, Lan Y, Zhang X, Gillies SD. The role of ADCC effector function in the antitumor activity of anti-EGFR antibodies in a mouse xenograft model. Clin Cancer Res 2003; 9:6069S.
36. Tabernero J, Rojo F, Jimenez E, Montaner I, Santome L, Guix M, Rosen O, Kovar A, Salazar R, Baselga J. A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-(q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with advanced tumors. Proc Am Soc Clin Oncol 2003; 22:192.
37. Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced nonsmall-cell lung cancer (NSCLC). Ann Oncol 2006; 17:1007-13.
38. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66.
39. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4. 41. Baars A, Buter J, Pinedo H. Making use of the primary tumour. BioEssays 2002; 25.1:79-86.
40. de Kleijn EM, Punt CJ. Biological therapy of colorectal cancer. Eur J Cancer 2002; 38:1016-22.
41. Sondak VK, Sabel MS, Mulé JJ. Allogeneic and autologous melanoma vaccines: Where have we been and where are we going? Clin Cancer Res 2006; 12:2337s-2341s.
42. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG, Pinedo HM. Active specific immunotherapy for stage II and stage III human colon cancer: A randomized trial. Lancet 1999; 353:345-50.
43. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95:13141-6.
44. Nencioni A, Brossart P. Cellular immunotherapy with dendritic cells in cancer: Current status. Stem Cells 2004; 22:501-13.
45. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 2002; 99:1517-26.
46. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15:138-47.
47. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18:245-73.
48. Pinzon-Charry A, Schmidt C, Lopez JA. Dendritic cell immunotherapy for breast cancer. Expert Opin Biol Ther 2006; 6:591-604.
49. Sullenger BA, Gilboa E. Emerging clinical applications of RNA. Nature 2002; 418:252-58.
50. Sudowe S, Ludwig-Portugall I, Montermann E, Ross R, Reske-Kunz AB. Transcriptional targeting of dendritic cells in gene gun-mediated DNA immunizations favors the induction of type 1 immune responses. Mol Ther 2003; 8:567-75.
51. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997; 89:293-300.
52. Hua JY, Huang RW. In vitro study of cytotoxic T lymphocyte activation by antigen-loaded dendritic cells for killing of K562 cells. Nan Fang Yi Ke Da Xue Xue Bao 2006; 5:617-9.
53. Chen W, Rains N, Young D, Stubbs RS. Dendritic cell-based cancer immunotherapy: Potential for treatment of colorectal cancer? J Gastroenterol Hepatol 2000; 15:698-705.
54. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52-8.
55. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 2001; 48:347-51.
56. Lesterhuis WJ, de Vries IJ, Schuurhuis DH, Boullart AC, Jacobs JF, de Boer AJ, Scharenborg NM, Brouwer HM, van de Rakt MW, Figdor CG, Ruers TJ, Adema GJ, Punt CJ. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: Antigen-specific T cell responses in DTH skin tests. Ann Oncol 2006; 17:974-80.
57. Saha A, Chatterjee SK, Foon KA, Bhattacharya-Chatterjee M. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen. Immunology 2006; 118:483-96.
58. Spendlove L, Li L, Potter V, Christiansen D, Loveland BE, Durrant LG. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Eur J Immunol 2000; 30:2944-53.
59. Kawano K, Ferrone S, Ioannides CG. Functional idiotopes: Tumor antigen-directed expression of CD8+ T-cell epitopes nested in unique NH2-terminal VH sequence of antiidiotypic antibodies? Cancer Res 2005; 65:6001-4.
60. Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler H, Bhattacharya-Chatterjee M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995; 96:334-42.
61. Foon KA, John WJ, Chakraborty M, Sherratt A, Garrison J, Flett M, Bhattacharya-Chatterjee M. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 1997; 3:1267-76.
62. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, Kashala O, Chatterjee SK, Bhattacharya-Chatterjee M. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999; 17:2889-95.
63. Chong G, Bhatnagar A, Cunningham D, Cosgriff TM, Harper PG, Steward W, Bridgewater J, Moore M, Cassidy J, Coleman R, Coxon F, Redfern CH, Jones JJ, Hawkins R, Northfelt D, Sreedharan S, Valone F, Carmichael J. Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol 2006; 17:437-42.
64. Hartung G, Hofheinz RD, Dencausse Y, Sturm J, Kopp-Schneider A, Dietrich G, Fackler-Schwalbe I, Bornbusch D, Gonnermann M, Wojatschek C, Lindemann W, Eschenburg H, Jost K, Edler L, Hochhaus A, Queisser W. Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: A multicenter randomized phase III study. Onkologie 2005; 28:347-50.